Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.-Reference-Cited by-同舟云学术

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:8023-8023
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Antonia Scott Joseph¹,Gettinger Scott N.²,Chow Laura Quan Man³,Juergens Rosalyn A.⁴,Borghaei Hossein⁵,Shen Yun⁶,Harbison Christopher⁶,Chen Allen C.⁶,Ready Neal⁷,Rizvi Naiyer A.⁸

Affiliation:

1. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

2. Yale Cancer Center, New Haven, CT

3. University of Washington, Seattle, WA

4. Juravinski Cancer Centre, Hamilton, ON, Canada

5. Fox Chase Cancer Center, Philadelphia, PA

6. Bristol-Myers Squibb, Princeton, NJ

7. Duke University Medical Center, Durham, NC

8. Memorial Sloan-Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.8023

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis;Current Oncology;2022-11-22

2. Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future;Integrative Cancer Therapies;2022-01

3. A Bayesian network meta‐analysis of comparison of cancer therapeutic vaccines for melanoma;Journal of the European Academy of Dermatology and Venereology;2021-06-29

4. Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology;Personalized Medicine;2020-09

5. Recent advances in the clinical development of immune checkpoint blockade therapy;Cellular Oncology;2019-06-14